CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers

Biomacromolecules. 2015 Aug 10;16(8):2412-7. doi: 10.1021/acs.biomac.5b00653. Epub 2015 Jul 22.

Abstract

CXCR4 is a cell membrane receptor that is overexpressed in triple-negative breast cancers and implicated in growth and metastasis of this disease. Using electrohydrodynamic cojetting, we prepared multicompartmental drug delivery carriers for CXCR4 targeting. The particles are comprised of a novel poly(lactide-co-glycolide) derivative that allows for straightforward immobilization of 1,1'-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] (Plerixafor), a small molecule with affinity for CXCR4. Targeted nanocarriers are selectively taken up by CXCR4-expressing cells and effectively block CXCR4 signaling. This study suggests that CXCR4 may be an effective target for nanocarrier-based therapies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Benzylamines
  • Cell Line, Tumor
  • Cyclams
  • Drug Delivery Systems
  • Female
  • Heterocyclic Compounds / administration & dosage*
  • Heterocyclic Compounds / chemistry
  • Humans
  • Nanoparticles / administration & dosage*
  • Receptors, CXCR4 / antagonists & inhibitors*
  • Triple Negative Breast Neoplasms / drug therapy*
  • Triple Negative Breast Neoplasms / pathology

Substances

  • Benzylamines
  • CXCR4 protein, human
  • Cyclams
  • Heterocyclic Compounds
  • Receptors, CXCR4
  • plerixafor